

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Birchmeier et al.

GAU 1653  
Examiner C. M. Kam

Serial No. 09/641,104

Filed on August 17, 2000

For: Means for Therapy of Human Diseases, etc.

Attorney's Docket 0107-028P

Commissioner of Patents  
Washington DC 20231

Sir:

Further to the supplemental response filed on May 30, 2002, and the subsequent telephone conversation with the examiner, the applicant hereby provisionally elects the first sequence of claim 20. The requirement is traversed.


The reason for the traverse is that, as it should be clearly recognized by a person with average skill in gene technology, the 7 sequences of claim 20 belong together, because they are representative of the single peptide, that of the human  $\beta$ -catenine, and a single sequence is meaningless without all of the others. Therefore, the election requirement does not make any sense.

Accordingly, it is respectfully requested that the 7 sequences of claim 20 be examined together..

Respectfully submitted

Goodwin Procter L.L.P.  
599 Lexington Avenue, 40<sup>th</sup> floor  
New York 10022

(212)813-8835

  
Gabriel P. Katona, attorney of record

It is hereby certified that this is being mailed on June 20, 2002



Attorney's Docket: 0107-028P  
S.N. 09/641,104  
Date Mailed: June 20, 2002

**RECEIPT IS HEREBY ACKNOWLEDGED:**

- 1) Further Response to May 15 Office letter